Wilson Disease Clinical Trials and Treatments

Wilson disease is caused by changes (mutations) in both copies of a gene called ATP7B, located on chromosome 13. ATP7B contains the instructions for a protein that lives inside liver cells (hepatocytes) and acts like a copper exporter. Normally, this protein loads copper onto ceruloplasmin (a copper-carrying protein in the blood) and pushes excess copper out of the liver into bile, where it leaves the body in stool. When ATP7B is broken, the body cannot get rid of copper through this route. Copper builds up first in the liver, then spills into the bloodstream and deposits in the brain, the eyes, the kidneys, and other organs. Free copper (copper not bound to ceruloplasmin) is chemically reactive and damages the tissues it accumulates in.

The disease can show up in very different ways from one patient to the next. The liver pattern can range from mildly elevated liver enzymes (transaminases) with no symptoms, through chronic liver inflammation (hepatitis), to scarring of the liver (cirrhosis) that may or may not still be functioning. In about 3% to 5% of patients the first sign is sudden, severe liver failure (acute liver failure), with breakdown of red blood cells (hemolysis) and impaired blood clotting (coagulopathy), which needs an emergency liver transplant; without one, this form is almost always fatal. A transplant is also the option when medicines fail. The neurologic pattern can include tremor, abnormal muscle contractions (dystonia), Parkinson-like slowness and stiffness, slurred speech (dysarthria), difficulty swallowing (dysphagia), and balance and walking problems. Brain MRI in these patients often shows changes in the deep brain structures that control movement (the basal ganglia); in advanced neurologic disease it can show a pattern in the midbrain called the face-of-the-giant-panda sign. The psychiatric pattern can include depression, personality changes, impulsivity, and in some patients psychosis, and is sometimes the first thing a family or doctor notices.

Diagnosis combines clinical clues with lab tests and genetic confirmation. Suggestive findings include low blood levels of ceruloplasmin, high copper levels in a 24-hour urine collection, the presence of Kayser-Fleischer rings on a slit-lamp eye exam, high copper measured directly in a small piece of liver (liver biopsy), and identifying mutations in both copies of ATP7B on genetic testing. The Leipzig diagnostic score combines these findings into a validated scoring framework that doctors use to confirm or rule out Wilson disease. The American Association for the Study of Liver Diseases (AASLD) 2022 Practice Guidance and the European EASL-ERN guidelines from 2025 are the main references for diagnosis and management. Doctors track treatment with 24-hour urine copper, serum copper and ceruloplasmin (used to estimate the copper not bound to ceruloplasmin), blood counts, urine tests and liver tests, usually at least twice a year.

Untreated Wilson disease is fatal. With early diagnosis and lifelong treatment, life expectancy and quality of life can approach normal, but skipping or stopping medicine can trigger liver failure. Treatment continues through pregnancy, usually at a lower chelator dose, and people on penicillamine are advised to keep dietary copper low, avoiding foods such as liver, shellfish, nuts, chocolate and mushrooms. Patients found before symptoms start (most often through screening of family members) and started on treatment quickly have the best outcomes. Patients who already have neurologic symptoms may have lasting effects even after copper levels are well controlled, which is why screening at-risk relatives matters so much. Wilson disease is the clinical mirror image of Menkes disease. Both diseases are caused by broken copper transporters, but Wilson (the ATP7B transporter) causes copper to build up to toxic levels, while Menkes (the ATP7A transporter) causes copper deficiency in the brain and connective tissue.

Wilson disease is autosomal recessive, meaning a person must inherit two altered copies of the ATP7B gene (one from each parent) to develop the disease. Both sexes are affected equally, and the disease has been described in every population studied. Carriers of a single ATP7B variant are typically asymptomatic.

Most patients first develop symptoms between ages 4 and 40, though it has been diagnosed from age 3 into the 70s (AASLD). The hepatic phenotype tends to dominate in children and adolescents, while neurologic and psychiatric phenotypes are more common in patients diagnosed in their 20s and 30s. Asymptomatic siblings of an affected patient should be screened biochemically and genetically, since starting treatment before symptoms develop offers the best outcomes.

Charity funds and drugmaker programs for Wilson Disease, checked at the source.

Open the full patient assistance finder →

Loading side effect data...

Finding labs...